L Blomqvist1, S Carlsson2, P Gjertsson3, E Heintz4, M Hultcrantz4, I Mejare4, O Andrén5. 1. Department of Diagnostic Radiology, Karolinska University Hospital, Solna, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Electronic address: lennart.k.blomqvist@ki.se. 2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Urology, Karolinska University Hospital, Solna, Sweden. 3. Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. 4. The Swedish Council on Health Technology Assessment, Stockholm, Sweden. 5. School of Health and Medical Sciences, Örebro University, Örebro, Sweden; Department of Urology, Örebro University Hospital, Örebro, Sweden.
Abstract
OBJECTIVE: To assess the diagnostic accuracy of imaging technologies for detecting prostate cancer in patients with elevated PSA-values or suspected findings on clinical examination. METHODS: The databases Medline, EMBASE, Cochrane, CRD HTA/DARE/NHS EED and EconLit were searched until June 2013. Pre-determined inclusion criteria were used to select full text articles. Risk of bias in individual studies was rated according to QUADAS or AMSTAR. Abstracts and full text articles were assessed independently by two reviewers. The performance of diagnostic imaging was compared with systematic biopsies (reference standard) and sensitivity and specificity were calculated. RESULTS: The literature search yielded 5141 abstracts, which were reviewed by two independent reviewers. Of these 4852 were excluded since they did not meet the inclusion criteria. 288 articles were reviewed in full text for quality assessment. Six studies, three using MRI and three using transrectal ultrasound were included. All were rated as high risk of bias. Relevant studies on PET/CT were not identified. CONCLUSION: Despite clinical use, there is insufficient evidence regarding the accuracy of imaging technologies for detecting cancer in patients with suspected prostate cancer using TRUS guided systematic biopsies as reference standard.
OBJECTIVE: To assess the diagnostic accuracy of imaging technologies for detecting prostate cancer in patients with elevated PSA-values or suspected findings on clinical examination. METHODS: The databases Medline, EMBASE, Cochrane, CRD HTA/DARE/NHS EED and EconLit were searched until June 2013. Pre-determined inclusion criteria were used to select full text articles. Risk of bias in individual studies was rated according to QUADAS or AMSTAR. Abstracts and full text articles were assessed independently by two reviewers. The performance of diagnostic imaging was compared with systematic biopsies (reference standard) and sensitivity and specificity were calculated. RESULTS: The literature search yielded 5141 abstracts, which were reviewed by two independent reviewers. Of these 4852 were excluded since they did not meet the inclusion criteria. 288 articles were reviewed in full text for quality assessment. Six studies, three using MRI and three using transrectal ultrasound were included. All were rated as high risk of bias. Relevant studies on PET/CT were not identified. CONCLUSION: Despite clinical use, there is insufficient evidence regarding the accuracy of imaging technologies for detecting cancer in patients with suspected prostate cancer using TRUS guided systematic biopsies as reference standard.
Authors: Borna K Barth; Pieter J L De Visschere; Alexander Cornelius; Carlos Nicolau; Hebert Alberto Vargas; Daniel Eberli; Olivio F Donati Journal: Radiology Date: 2017-03-27 Impact factor: 11.105
Authors: Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Spencer C Behr; Rahul Aggarwal; Henry F VanBrocklin; Robert R Flavell; Kenneth Gao; Eric J Small; Joseph Blecha; Salma Jivan; Thomas A Hope; Jeffry P Simko; John Kurhanewicz; Susan M Noworolski; Natalie J Korn; Romelyn De Los Santos; Matthew R Cooperberg; Peter R Carroll; Hao G Nguyen; Kirsten L Greene; Beatrice Langton-Webster; Clifford E Berkman; Youngho Seo Journal: J Nucl Med Date: 2018-11-21 Impact factor: 10.057
Authors: Kenneth J Pienta; Michael A Gorin; Steven P Rowe; Peter R Carroll; Frédéric Pouliot; Stephan Probst; Lawrence Saperstein; Mark A Preston; Ajjai S Alva; Akash Patnaik; Jeremy C Durack; Nancy Stambler; Tess Lin; Jessica Jensen; Vivien Wong; Barry A Siegel; Michael J Morris Journal: J Urol Date: 2021-02-26 Impact factor: 7.450